Tag: release

NEWARK, Del., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Artesian Resources Corporation (Nasdaq: ARTNA) announced today that its Board of Directors has declared a regular quarterly dividend on the company’s Class A and Class B Common Stock. The quarterly dividend of $0.3074 per share is payable August 25, 2025 to shareholders of record at the close of business on August 15, 2025, providing an annualized dividend of $1.2296 per share.

NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Transaction in Own Shares   

EU backs AIxBlock’s mission to decentralize AI development and automate infrastructure workflows—starting with a €1.5M grant and €61.5M in non-dilutive funding pipeline

ST. JAMES, N.Y., Aug. 04, 2025 (GLOBE NEWSWIRE) --  Gyrodyne, LLC (NASDAQ:GYRO), an owner and manager of a diversified portfolio of real estate properties, today announced that its subsidiary, GSD Flowerfield, LLC, has entered into a purchase and sale agreement (the “Agreement”) for the sale of approximately 49 acres of vacant land located within the Company’s Flowerfield complex in St. James, New York (the “Property”) to B2K Smithtown LLC (“B2K”).

COMPAGNIE DE L'ODET

So far this year, the Avista Foundation has awarded approximately $491,950 in grants to support local communities

CAISSE REGIONALE DE CREDIT AGRICOLE MUTUEL ALPES PROVENCE

ATLANTA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information, including allegations that: (1) Defendants recklessly overstated the IGNYTE trial’s prospects, given material issues that defendants knew or should have known of, which resulted in the FDA deeming the IGNYTE trial inadequate and not well-controlled; and (2) as a result, defendants’ statements about Replimune’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all times.